Verrica Pharmaceuticals Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Verrica Pharmaceuticals Inc. (VRCA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.21M, a 36.60% increase year-over-year.
- Verrica Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $897.00K, a 12.57% decline year-over-year.
- Verrica Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $718.00K, a 65.94% decline year-over-year.
- Verrica Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $888.00K, a 60.14% decline year-over-year.
- Verrica Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $3.32M, a 53.69% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.16M, a 50.17% decline from fiscal 2023.
- Verrica Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $14.38M, a 188.39% increase from fiscal 2022.
- Verrica Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.99M, a 17.64% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.21M 10-Q · filed 2026-08-06 | $2.11M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $897.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $3.32M 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $718.00K 10-Q · filed 2025-11-14 | $1.61M derived: sum of 2 quarters · filed 2026-08-06 | $2.63M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $888.00K 10-Q · filed 2026-08-06 | $1.91M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.03M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $7.16M 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $2.11M 10-Q · filed 2025-11-14 | $4.34M derived: sum of 2 quarters · filed 2025-11-14 | $6.41M derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $2.23M 10-Q · filed 2025-11-14 | $4.30M derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $2.07M 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $14.38M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $9.66M 10-Q · filed 2024-11-05 | $11.21M derived: sum of 2 quarters · filed 2024-11-05 | $12.30M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $1.54M 10-Q · filed 2024-11-05 | $2.64M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $1.09M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $4.99M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $1.41M 10-Q · filed 2023-11-09 | $2.50M derived: sum of 2 quarters · filed 2023-11-09 | $3.81M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.08M 10-Q · filed 2023-11-09 | $2.40M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $1.32M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $6.05M 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $1.48M 10-Q · filed 2022-11-07 | $3.33M derived: sum of 2 quarters · filed 2022-11-07 | $4.73M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $1.85M 10-Q · filed 2022-11-07 | $3.25M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $1.40M 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $9.82M 10-K · filed 2022-03-02 | |||
| 2020-09-30 | $1.23M 10-Q · filed 2021-11-12 | $2.48M derived: sum of 2 quarters · filed 2021-11-12 | $3.48M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $1.25M 10-Q · filed 2021-11-12 | $2.25M derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $998.00K 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $3.33M 10-K · filed 2021-03-17 | |||
| 2019-09-30 | $905.00K 10-Q · filed 2020-11-09 | $1.75M derived: sum of 2 quarters · filed 2020-11-09 | $2.53M derived: sum of 3 quarters · filed 2020-11-09 | $1.68M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $846.00K 10-Q · filed 2020-11-09 | $1.63M derived: sum of 2 quarters · filed 2020-11-09 | $778.00K derived: sum of 3 quarters · filed 2020-11-09 | $1.46M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-03-31 | $780.00K 10-Q · filed 2020-11-09 | -$68.00K derived: sum of 2 quarters · filed 2020-11-09 | $615.00K derived: sum of 3 quarters · filed 2020-11-09 | $1.39M derived: sum of 4 quarters · filed 2020-11-09 |
| 2018-12-31 | -$848.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$165.00K derived: sum of 2 quarters · filed 2020-03-13 | $614.00K derived: sum of 3 quarters · filed 2020-03-13 | $2.25M 10-K · filed 2020-03-13 |
| 2018-09-30 | $683.00K 10-Q · filed 2019-11-06 | $1.46M derived: sum of 2 quarters · filed 2019-11-06 | $3.10M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $779.00K 10-Q · filed 2019-11-06 | $1.58M 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | $135.00K 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $82.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |